Cardiovascular Risks in Testicular Cancer: Assessment, Prevention, and Treatment
AbstractPurpose of ReviewTesticular cancer (TC) is the leading cancer in men between 18 and 39 years of age. Current treatment involves tumor resection followed by surveillance and/or one or more lines of cisplatin-based chemotherapy (CBCT) and/or bone marrow transplant (BMT). Ten years after treatment, CBCT has been associated with significant atherosclerotic cardiovascular disease (CVD) i ncluding myocardial infarction (MI), stroke, and heightened rates of hypertension, dyslipidemia, diabetes mellitus, and metabolic syndrome (MetS). Additionally, low testosterone levels and hypogonadism contribute to MetS and may further drive CVD.Recent FindingsCVD in TCS has been associated with worse physical functioning accompanied by role limitations, decreased energy, and decreased overall health. Exercise may play a role in ameliorating these effects.SummarySystematic CVD screening practices are needed at TC diagnosis and in survivorship. We encourage a multidisciplinary partnership between primary care physicians, cardiologists, cardio-oncologists, medical oncologists, and survivorship providers to address these needs.
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
More News: Bone Marrow Transplant | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chemotherapy | Diabetes | Diabetes Mellitus | Endocrinology | Heart | Heart Attack | Hypertension | Low Testosterone | Metabolic Syndrome | Partnerships | Primary Care | Sports Medicine | Stroke | Testicular Cancer | Transplants